Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA complete response letter for sutimlimab cites third-party manufacturing issues

Nov. 16, 2020

Rallybio begins phase I/II study of RLYB-211 for fetal and neonatal alloimmune thrombocytopenia

Nov. 11, 2020

Medshine Discovery synthesizes new factor XIa inhibitors

Nov. 6, 2020

Adakveo approved in Europe to prevent VOCs in patients with sickle cell disease

Nov. 4, 2020

A novel inducer of fetal hemoglobin with improved PK and PD properties

Nov. 3, 2020

INSERM and collaborators describe hematopoietic stem cells including beta globin gene

Nov. 2, 2020

IND in effect for Fulcrum's phase I study of FTX-6058 for sickle cell disease

Oct. 5, 2020

Roche opens enrollment in phase III studies of crovalimab for PNH

Oct. 2, 2020

Discovery of new potent, selective and orally bioavailable inhibitors of factor XI

Oct. 2, 2020

BCX-9930 shows clinical benefit as monotherapy in treatment-naive patients with PNH

Oct. 1, 2020

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...